BACKGROUND: In retrospective studies, estimates of hastened dying among seriously ill patients range from <2% in one national survey to as much as 20% in end-stage disease cohorts. OBJECTIVE: To examine, in prospective studies, dying patients in the months before death, in order to understand the wish to die. METHODS: Patients with advanced ALS with a high likelihood of death or need for tracheostomy within 6 months were identified. Patients were assessed monthly with an extensive psychosocial interview, including a diagnostic interview for depression. Family caregivers were interviewed on the same schedule and also after patient deaths. RESULTS: Eighty patients with ALS were enrolled, 63% of eligible patients; 53 died over follow-up. Ten (18.9%) of the 53 expressed the wish to die, and 3 (5.7%) hastened dying. Patients expressing the wish to die did not differ in sociodemographic features, ALS severity, or perceived burden of family caregivers. They were more likely to meet criteria for depression, but differences were smaller when suicidality was excluded from the depression interview. Patients who expressed the wish to die reported less optimism, less comfort in religion, and greater hopelessness. Compared with patients unable to act on the wish to die, patients who hastened dying reported reduction in suffering and increased perception of control over the disease in the final weeks of life. CONCLUSION: These findings suggest caution in concluding that the desire to hasten dying in end-stage disease is simply a feature of depression.
BACKGROUND: In retrospective studies, estimates of hastened dying among seriously ill patients range from <2% in one national survey to as much as 20% in end-stage disease cohorts. OBJECTIVE: To examine, in prospective studies, dying patients in the months before death, in order to understand the wish to die. METHODS:Patients with advanced ALS with a high likelihood of death or need for tracheostomy within 6 months were identified. Patients were assessed monthly with an extensive psychosocial interview, including a diagnostic interview for depression. Family caregivers were interviewed on the same schedule and also after patientdeaths. RESULTS: Eighty patients with ALS were enrolled, 63% of eligible patients; 53 died over follow-up. Ten (18.9%) of the 53 expressed the wish to die, and 3 (5.7%) hastened dying. Patients expressing the wish to die did not differ in sociodemographic features, ALS severity, or perceived burden of family caregivers. They were more likely to meet criteria for depression, but differences were smaller when suicidality was excluded from the depression interview. Patients who expressed the wish to die reported less optimism, less comfort in religion, and greater hopelessness. Compared with patients unable to act on the wish to die, patients who hastened dying reported reduction in suffering and increased perception of control over the disease in the final weeks of life. CONCLUSION: These findings suggest caution in concluding that the desire to hasten dying in end-stage disease is simply a feature of depression.
Authors: Harvey Max Chochinov; Thomas Hack; Thomas Hassard; Linda J Kristjanson; Susan McClement; Mike Harlos Journal: Lancet Date: 2002 Dec 21-28 Impact factor: 79.321
Authors: B Rosenfeld; W Breitbart; M Galietta; M Kaim; J Funesti-Esch; H Pessin; C J Nelson; R Brescia Journal: Cancer Date: 2000-06-15 Impact factor: 6.860
Authors: K G Wilson; J F Scott; I D Graham; J F Kozak; S Chater; R A Viola; B J de Faye; L A Weaver; D Curran Journal: Arch Intern Med Date: 2000-09-11
Authors: Jan H Veldink; John H J Wokke; Gerrit van der Wal; J M B Vianney de Jong; Leonard H van den Berg Journal: N Engl J Med Date: 2002-05-23 Impact factor: 91.245
Authors: Maud Maessen; Jan H Veldink; Bregje D Onwuteaka-Philipsen; Henk T Hendricks; Helenius J Schelhaas; Hepke F Grupstra; Gerrit van der Wal; Leonard H van den Berg Journal: J Neurol Date: 2014-07-15 Impact factor: 4.849
Authors: Hiroshi Mitsumoto; Pam Factor-Litvak; Howard Andrews; Raymond R Goetz; Leslie Andrews; Judith G Rabkin; Martin McElhiney; Jeri Nieves; Regina M Santella; Jennifer Murphy; Jonathan Hupf; Jess Singleton; David Merle; Mary Kilty; Daragh Heitzman; Richard S Bedlack; Robert G Miller; Jonathan S Katz; Dallas Forshew; Richard J Barohn; Eric J Sorenson; Bjorn Oskarsson; J Americo M Fernandes Filho; Edward J Kasarskis; Catherine Lomen-Hoerth; Tahseen Mozaffar; Yvonne D Rollins; Sharon P Nations; Andrea J Swenson; Jeremy M Shefner; Jinsy A Andrews; Boguslawa A Koczon-Jaremko Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2014-02-24 Impact factor: 4.092
Authors: Ryan E Lawrence; David Brent; J John Mann; Ainsley K Burke; Michael F Grunebaum; Hanga C Galfalvy; Maria A Oquendo Journal: J Nerv Ment Dis Date: 2016-11 Impact factor: 2.254
Authors: Peter M Andersen; Magdalena Kuzma-Kozakiewicz; Jürgen Keller; Helena E A Aho-Oezhan; Katarzyna Ciecwierska; Natalia Szejko; Cynthia Vázquez; Sarah Böhm; Gisela Badura-Lotter; Thomas Meyer; Susanne Petri; Katharina Linse; Andreas Hermann; Olof Semb; Erica Stenberg; Simona Nackberg; Johannes Dorst; Ingo Uttner; Ann-Cristin Häggström; Albert C Ludolph; Dorothée Lulé Journal: J Neurol Date: 2018-05-04 Impact factor: 4.849